Cyclosporine in Dry Eye: A Review
Keywords:
Cyclosporine, Dry Eye, Keratoconjunctivitis Sicca, Sjogren’s Syndrome
Abstract
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of population worldwide. Various environmental, nutritional, hormonal and external factors altering the functional integrity of the ocular surface components have been implicated. The imbalance results in changes in epithelium causing desiccation and setting up an inflammatory cascade which causes dysregulation of the ocular surface regeneration system. With increasing knowledge of the etiology and mechanisms involved in the development of dry eye, role of cyclosporine A has been well established with numerous clinical studies. This has led to the US Food and Drug Administration (FDA) approval of the drug for the treatment of dry eye. This article reviews the pathology of development of dry eye, pharmacology of cyclosporine, use of cyclosporine A in dry eye established via various animal and clinical studies.
Downloads
Download data is not yet available.
References
1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007 Apr;5(2):75-92. [PubMed]
2. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop. Ocul Surf .2007 Apr;5(2):108-52. Review. [PubMed]
3. Schaumberg DA, Dana MR, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009 Jun;127(6):763-8. [PubMed]
4. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003 Aug;136(2):318-26. [PubMed]
5. Epidemiology. DEWS Subcommittee, Smith JA, Albeitz J, et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocul Surf .2007 Apr;5(2):93-107. Review. [PubMed]
6. Sahai A, Malik P. Dry eye: prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol. 2005 Jun;53(2):87-91. [PubMed]
7. Sharma A, Hindman HB. Aging: a predisposition to dry eyes. J Ophthalmol. 2014;2014:781683. doi: 10.1155/2014/781683. Epub 2014 Aug 14. Review. [PubMed]
8. Schein OD, Munoz B, Teilsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997 Dec;124(6):723-8. [PubMed]
9. Moss SE, Klein R, Klein BEK. Prevalence of and risk factors for dry eye syndrome. Arch of Ophthalmol. 2000 Sep;118(9):1264-68. [PubMed]
10. Bhavsar AS, Bhavsar SG, Jain SM. A review on recent advances in dry eye: Pathogenesis and management. Oman J Ophthalmol. 2011 May;4(2):50-6. Doi:10.4103/0974-620X.83653. [PubMed]
11. Tomlinson A, Madden LC, Simmons PA. Effectiveness of dry eye therapy under conditions of environmental stress. Curr Eye Res. 2013 Feb;38(2):229-36. doi:10.3109/02713683.2012.757323. Epub 2013 Jan 7. [PubMed]
12. Gupta N, Prasad I, Himashree G, D’Souza P. Prevalence of dry eye at high altitude: a case controlled comparative study. High Alt Med Biol. 2008 Winter;9(4):327-34. doi:10.1089/ham.2007.1055. [PubMed]
13. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-12. Epub 2009 Jul 14. [PubMed]
14. Le Q, Zhou X, Ge L, Wu L, Hong J, Xu J. Impact of dry eye syndrome on vision-related quality of life in a non-clinic based general population. BMC Ophthalmol. 2012 Jul 16:12:22. doi.10.1186/1471-2415-12-22. [PubMed]
15. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision related quality of life. Am J Ophthalmol. 2007 Mar;143(3):409-15. Epub 2007 Jan 2. [PubMed]
16. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 2007 Apr;5(2);163-78. [PubMed]
17. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 2011 Jul;22(4):279-82. doi.: 10.1097/ICU.0b013e3283477d23. Review. [PubMed]
18. Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008 Dec;2(4):829-36. [PubMed]
19. Research in dry eye: report of the Research Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007 Apr;5(2):179-93. [PubMed]
20. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun;330(26):1841-5. [PubMed]
21. Kamaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory disease. Ophthalmology. 2010 Mar;117(3):576-84. doi: 10.1016/j. ophtha. 2009.08010. [PubMed]
22. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. Solvent-dependent. conformation and hydrogen-bonding capacity of cyclosporine A: evidence from partition coefficients and molecular dynamics simulation. J Med Chem. 1993 Nov;36(24):3757-64. [PubMed]
23. Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol and eye dis. 2014 Jun; 24(6):37-42. doi: 104137∕OEDS16067. e collection 2014. [PubMed]
24. Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010 Jun; 26(2):157-164. doi:10.1089/jop.2009.0091. [PubMed]
25. Thomas PB, Samant DM, Zhu Z, et al. Long term cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryodenitis. J Ocul Pharmacol Ther. 2009 Jun;25(3):285-92. doi:10.1089/jop.2008.0138.
26. Izci C, Celik I, Alkan F, Erol M, Sui E. Clinical and light microscopic studies of the conjunctival tissue of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Biotech Histochem. 2015 Apr;90(3):223-30. doi.10.3109/105202952014.930177. Epub 2015 Mar 6.
27. O’Connell S, Slattery C, Ryan MP, McMorrow T. Sirolimus enhances cyclosporine A induced cytotoxicity in human renal glomerular mesangial cells. J Transplant. 2012;2012:980910.doi:10.1155/2012/980910. Epub 2012 Jan 23.
28. Henry ML, Elkhammas EA, Davies EA, Ferguson RM. A clinical trial of cysclosporine G in cadaveric renal transplantation. Pediatr Nephrol. 1995;9(suppl):S49-51. [PubMed]
29. Yavuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cylosporin A delivery. Scientific World J. 2012;2012:194848. doi:10.1100/2012/194848. Epub 2012 Apr 24. [PubMed]
30. Williams DL. A comparative approach to topical cyclosporine therapy. Eye (Lond). 1997;11(pt4):453-64. [PubMed]
31. Kauss Hornecker M, Charles Weber S, Brandely Piat ML, Darrodes M, Jomma K, Chast F. Cyclosporine eye drops: A 4 year retrospective study. J Fr Ophtalmol. 2015 Oct;38(8):700-708. doi: 10.1016/j.jfo.2015.02.008. Epub 2015 Sep 11. French. [PubMed]
32. Perez-Rico C, Germain F, Castro Rebollo M, Moreno Salqueiro A, Teus MA. Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthalmol. 2013 Aug 18;6(4):471-4. doi: 10.3980/j.issn.2222-3959.2013.04.12. eCollection 2013. [PubMed]
33. Byun YS, Rho CR, Cho K, Choj JA, Na KS, Joo CK. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: A prospective, multicenter, open-label surveillance study. Korean J Ophthalmol. 2011 Dec;25(6):369-74. doi: 10.3341/kjo.2011.25.6.369. Epub 2011 Nov 2. [PubMed]
34. Prabhasawat P, Tesavibul N, Karnchanachetanee C, Kasemson S. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye..J Ocul Pharmacol Ther. 2013 Apr;29(3):372-7. doi: 10.1089/jop.2012.0009. Epub 2013 Jan 5. [PubMed]
35. Dastjerdi MH, Hamrah P, Dana R. High frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice daily regimen. Cornea. 2009 Dec;28(10):1091-6. doi:10.1097/ICO.0b013e3181a16472. [PubMed]
36. Deveci H, Kobak S. The efficacy of topical 0.05% cyclosporine A in patients with dry eye diseases associated with Sjogren’s syndrome. Int Ophthalmol. 2014 Oct;34(5):1043-8. doi:10.1007/s10792-014-990124. Epub 2014 Jan 19. [PubMed]
37. Egorova GB, Mitichkina TS, Fedorov AA, Shamsudinova AR. Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers. Vestn Oftalmol. 2015 Jan-Feb;131(1):36-4.2. [PubMed]
38. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013 Jun;27(3):167-71. doi:10.3341/kjo.2013.27.3.167. Epub 2013 Apr 8. [PubMed]
39. Toricelli AA, Santhiago MR, Wilson SE. Topical cyclosporine A treatment in corneal refractive surgery and patients with dry eye. J Refract Surg. 2014 Aug;30(8):558-64. doi:10.3428∕10810597X-20140711-09. [PubMed]
40. Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta analysis. Cornea. 2014 Jul;33(7):760-7. doi: 10.0197∕ICO:000000000000123. Review. [PubMed]
41. Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: physician’s evaluation of Cyclosporine satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971-6. doi: 10..2147/OPTH.S30261. Epub 2102 Nov 28.
2. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop. Ocul Surf .2007 Apr;5(2):108-52. Review. [PubMed]
3. Schaumberg DA, Dana MR, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009 Jun;127(6):763-8. [PubMed]
4. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003 Aug;136(2):318-26. [PubMed]
5. Epidemiology. DEWS Subcommittee, Smith JA, Albeitz J, et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocul Surf .2007 Apr;5(2):93-107. Review. [PubMed]
6. Sahai A, Malik P. Dry eye: prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol. 2005 Jun;53(2):87-91. [PubMed]
7. Sharma A, Hindman HB. Aging: a predisposition to dry eyes. J Ophthalmol. 2014;2014:781683. doi: 10.1155/2014/781683. Epub 2014 Aug 14. Review. [PubMed]
8. Schein OD, Munoz B, Teilsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997 Dec;124(6):723-8. [PubMed]
9. Moss SE, Klein R, Klein BEK. Prevalence of and risk factors for dry eye syndrome. Arch of Ophthalmol. 2000 Sep;118(9):1264-68. [PubMed]
10. Bhavsar AS, Bhavsar SG, Jain SM. A review on recent advances in dry eye: Pathogenesis and management. Oman J Ophthalmol. 2011 May;4(2):50-6. Doi:10.4103/0974-620X.83653. [PubMed]
11. Tomlinson A, Madden LC, Simmons PA. Effectiveness of dry eye therapy under conditions of environmental stress. Curr Eye Res. 2013 Feb;38(2):229-36. doi:10.3109/02713683.2012.757323. Epub 2013 Jan 7. [PubMed]
12. Gupta N, Prasad I, Himashree G, D’Souza P. Prevalence of dry eye at high altitude: a case controlled comparative study. High Alt Med Biol. 2008 Winter;9(4):327-34. doi:10.1089/ham.2007.1055. [PubMed]
13. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-12. Epub 2009 Jul 14. [PubMed]
14. Le Q, Zhou X, Ge L, Wu L, Hong J, Xu J. Impact of dry eye syndrome on vision-related quality of life in a non-clinic based general population. BMC Ophthalmol. 2012 Jul 16:12:22. doi.10.1186/1471-2415-12-22. [PubMed]
15. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision related quality of life. Am J Ophthalmol. 2007 Mar;143(3):409-15. Epub 2007 Jan 2. [PubMed]
16. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 2007 Apr;5(2);163-78. [PubMed]
17. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 2011 Jul;22(4):279-82. doi.: 10.1097/ICU.0b013e3283477d23. Review. [PubMed]
18. Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008 Dec;2(4):829-36. [PubMed]
19. Research in dry eye: report of the Research Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007 Apr;5(2):179-93. [PubMed]
20. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun;330(26):1841-5. [PubMed]
21. Kamaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory disease. Ophthalmology. 2010 Mar;117(3):576-84. doi: 10.1016/j. ophtha. 2009.08010. [PubMed]
22. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. Solvent-dependent. conformation and hydrogen-bonding capacity of cyclosporine A: evidence from partition coefficients and molecular dynamics simulation. J Med Chem. 1993 Nov;36(24):3757-64. [PubMed]
23. Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol and eye dis. 2014 Jun; 24(6):37-42. doi: 104137∕OEDS16067. e collection 2014. [PubMed]
24. Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010 Jun; 26(2):157-164. doi:10.1089/jop.2009.0091. [PubMed]
25. Thomas PB, Samant DM, Zhu Z, et al. Long term cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryodenitis. J Ocul Pharmacol Ther. 2009 Jun;25(3):285-92. doi:10.1089/jop.2008.0138.
26. Izci C, Celik I, Alkan F, Erol M, Sui E. Clinical and light microscopic studies of the conjunctival tissue of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Biotech Histochem. 2015 Apr;90(3):223-30. doi.10.3109/105202952014.930177. Epub 2015 Mar 6.
27. O’Connell S, Slattery C, Ryan MP, McMorrow T. Sirolimus enhances cyclosporine A induced cytotoxicity in human renal glomerular mesangial cells. J Transplant. 2012;2012:980910.doi:10.1155/2012/980910. Epub 2012 Jan 23.
28. Henry ML, Elkhammas EA, Davies EA, Ferguson RM. A clinical trial of cysclosporine G in cadaveric renal transplantation. Pediatr Nephrol. 1995;9(suppl):S49-51. [PubMed]
29. Yavuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cylosporin A delivery. Scientific World J. 2012;2012:194848. doi:10.1100/2012/194848. Epub 2012 Apr 24. [PubMed]
30. Williams DL. A comparative approach to topical cyclosporine therapy. Eye (Lond). 1997;11(pt4):453-64. [PubMed]
31. Kauss Hornecker M, Charles Weber S, Brandely Piat ML, Darrodes M, Jomma K, Chast F. Cyclosporine eye drops: A 4 year retrospective study. J Fr Ophtalmol. 2015 Oct;38(8):700-708. doi: 10.1016/j.jfo.2015.02.008. Epub 2015 Sep 11. French. [PubMed]
32. Perez-Rico C, Germain F, Castro Rebollo M, Moreno Salqueiro A, Teus MA. Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthalmol. 2013 Aug 18;6(4):471-4. doi: 10.3980/j.issn.2222-3959.2013.04.12. eCollection 2013. [PubMed]
33. Byun YS, Rho CR, Cho K, Choj JA, Na KS, Joo CK. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: A prospective, multicenter, open-label surveillance study. Korean J Ophthalmol. 2011 Dec;25(6):369-74. doi: 10.3341/kjo.2011.25.6.369. Epub 2011 Nov 2. [PubMed]
34. Prabhasawat P, Tesavibul N, Karnchanachetanee C, Kasemson S. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye..J Ocul Pharmacol Ther. 2013 Apr;29(3):372-7. doi: 10.1089/jop.2012.0009. Epub 2013 Jan 5. [PubMed]
35. Dastjerdi MH, Hamrah P, Dana R. High frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice daily regimen. Cornea. 2009 Dec;28(10):1091-6. doi:10.1097/ICO.0b013e3181a16472. [PubMed]
36. Deveci H, Kobak S. The efficacy of topical 0.05% cyclosporine A in patients with dry eye diseases associated with Sjogren’s syndrome. Int Ophthalmol. 2014 Oct;34(5):1043-8. doi:10.1007/s10792-014-990124. Epub 2014 Jan 19. [PubMed]
37. Egorova GB, Mitichkina TS, Fedorov AA, Shamsudinova AR. Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers. Vestn Oftalmol. 2015 Jan-Feb;131(1):36-4.2. [PubMed]
38. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013 Jun;27(3):167-71. doi:10.3341/kjo.2013.27.3.167. Epub 2013 Apr 8. [PubMed]
39. Toricelli AA, Santhiago MR, Wilson SE. Topical cyclosporine A treatment in corneal refractive surgery and patients with dry eye. J Refract Surg. 2014 Aug;30(8):558-64. doi:10.3428∕10810597X-20140711-09. [PubMed]
40. Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta analysis. Cornea. 2014 Jul;33(7):760-7. doi: 10.0197∕ICO:000000000000123. Review. [PubMed]
41. Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: physician’s evaluation of Cyclosporine satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971-6. doi: 10..2147/OPTH.S30261. Epub 2102 Nov 28.
CITATION
DOI: 10.17511/ijmrr.2015.i9.190
Published: 2015-10-31
How to Cite
1.
Gupta S. Cyclosporine in Dry Eye: A Review. Int J Med Res Rev [Internet]. 2015Oct.31 [cited 2024Apr.19];3(9):1037-41. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/375
Section
Review Article
OAI - Open Archives Initiative
